"BioAge Labs has entered a multi-year research collaboration with Novartis.
The partnership aims to discover and validate new therapeutic targets by studying the biological mechanisms underlying age-related diseases and the health benefits of physical exercise.
The collaboration will utilise BioAge’s proprietary discovery platform, which is built on decades of longitudinal human ageing data. The platform integrates health records, functional measurements, and advanced analytics, including machine learning, to identify the key factors influencing healthy ageing.
Insights from this platform will be combined with Novartis’ expertise in exercise biology to explore innovative approaches to therapeutic development.
The agreement includes upfront payments and research funding of up to $20 million, with potential milestone payments and royalties that could reach a total of $530 million.
Both companies retain the right to progress drug targets discovered through the partnership and will share reciprocal milestones and royalties as the collaboration advances.
This initiative highlights the increasing importance of ageing research in addressing diseases and improving health outcomes.
It also represents a significant step forward in leveraging human ageing data to develop transformative therapies that could benefit a broad range of conditions associated with ageing.